ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
The new facility is expected to significantly improve access to high-quality medical services for patients across Gujarat and neighbouring regions
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
This includes 14.3 million views on YouTube and 9.8 million views on Meta platforms to amplify preventive heart health message
Subscribe To Our Newsletter & Stay Updated